# Study of XB010 in Subjects With Solid Tumors

> **NCT06545331** · PHASE1 · RECRUITING · sponsor: **Exelixis** · enrollment: 396 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors
- Esophageal Squamous Cell Cancer
- Head and Neck Squamous Cell Cancer
- NSCLC (Non-small Cell Lung Cancer)
- Hormone-receptor-positive Breast Cancer
- Triple Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** XB010
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06545331
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-06
- **Primary completion:** 2026-11-23
- **Final completion:** 2027-10-20
- **Target enrollment:** 396 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06545331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06545331, "Study of XB010 in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06545331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*